| abstract |
Enadenotuxireb (EnAd) augmented with a modified adenovirus, in particular a bispecific T cell engager (BiTE) comprising at least two binding domains, wherein at least one of the domains is a surface antigen on the T-cell of interest specific for adenovirus. Also provided are compositions, such as pharmaceutical formulations comprising the virus, use of the virus and viral formulations for treatment, such as in the treatment of cancer. The present disclosure also extends to a method of making a virus. |